• Explore /
  • Poster
  • / SOX plus bevacizumab versus SOX plus cetuximab as initial treatment of recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study): A phase II randomized study.

SOX plus bevacizumab versus SOX plus cetuximab as initial treatment of recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study): A phase II randomized study.

Abstract Poster

Authors

null

Shu Okamura

Department of Surgery, Suita Municipal Hospital, Suita, Japan;

Shu Okamura , Yujiro Nishizawa , Yoshinori Kagawa , Mitsunobu Imasato , Masakazu Miyake , Nobuyoshi Ohara , Yoshihito Ide , Ryoji Nonaka , Koki Tamai , Ken Konishi , Takeshi Kato , Genta Sawada , Mitsuyoshi Tei , Taroh Satoh , Norikatsu Miyoshi , Mamoru Uemura , Hidekazu Takahashi , Kohei Murata , Yuichiro Doki , Hidetoshi Eguchi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

UMIN000006706

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr 136)

DOI

10.1200/JCO.2023.41.4_suppl.136

Abstract #

136

Poster Bd #

G14

Abstract Disclosures

Similar Posters

First Author: Yu Sunakawa

First Author: Kaori Hayashi

First Author: Chiara Cremolini

First Author: Ewald Woell